Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (A) launched the 5987A single quadrupole mass selective detector with GC Assist, alongside its MassHunter 14 software. The detector combines with Agilent’s 8890B or 8860B gas chromatograph to form an integrated system for separating and identifying compounds.
Agilent says the detector delivers up to 25% faster scanning while maintaining data quality and uses up to 40% less energy than previous Agilent GC/MSD systems. GC Assist provides system monitoring, troubleshooting and maintenance guidance, including remote access within a laboratory’s secure network.
Agilent Technologies (NYSE: A) will release its fourth-quarter fiscal 2026 financial results after the market closes on Nov. 23, 2026. A conference call to discuss the results will follow at 1:30 p.m. PST that day.
A listen-only webcast will be accessible through the Events section of Agilent’s Investor Relations website. A recording will remain available on the website for 90 days.
Agilent Technologies (NYSE: A) and the University of Chicago announced a collaboration to establish a Center of Excellence for Energy Materials Research.
The center will be based at the university’s Pritzker School of Molecular Engineering and support its Energy Technologies Initiative. It will use Agilent instruments to investigate materials for next-generation batteries, including those used in electric vehicles, connected devices and grid-scale storage. Planned work includes developing analytical methods and research workflows with university researchers and other academic and industry partners.
Agilent Technologies (A) signed a definitive agreement to acquire digital pathology software provider Proscia for $240 million in cash at closing.
The all-cash transaction includes up to an additional $30 million tied to future performance milestones. Agilent expects closing early in its fiscal year 2027, subject to customary closing conditions. Proscia would join Agilent’s Life Sciences and Diagnostics Markets Group.
Proscia has trailing twelve months revenue exceeding $18 million and serves more than 4,000 laboratories, hospitals, and clinics, plus 16 of the top 20 pharmaceutical companies. Its platform holds FDA 510(k) clearance for primary diagnosis. Agilent expects the acquisition to add a recurring-revenue software business and expand its digital pathology and AI-enabled companion-diagnostics capabilities. The agreement builds on the companies’ September 2022 distribution partnership.
Agilent Technologies (NYSE: A) launched the NovoStation Sample Preparation System to automate sample preparation for laboratory flow cytometry workflows.
The platform automates reagent mixing and sample washing and connects with compatible Agilent flow cytometers. Paired with NovoCyte and NovoExpress software, it is designed to connect preparation with data acquisition. Agilent reported that validation studies reduced hands-on time by more than 90%, with data quality comparable to manual processing. The company will officially unveil NovoStation at the International Clinical Cytometry Society conference in Miami, taking place October 2–6, 2026.
Agilent Technologies (A) launched the BioTek Gen5 AI cell identification module for compatible BioTek automated imaging systems.
The software add-on brings AI-based cell identification and segmentation into Gen5 imaging analysis without conventional threshold setting or parameter tuning. It works within Gen5 on compatible Cytation and Lionheart automated imagers. Agilent says the module is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis across supported applications.
Agilent Technologies (A) launched the 4150 TapeStationDx system, 4200 TapeStationDx system and TapeStationDx software to bring its automated electrophoresis platform into regulated clinical NGS sample quality control workflows.
The CE-IVD-labeled systems are designed to standardize and document DNA and RNA quality control for clinical next-generation sequencing, with automated workflows to reduce manual errors and support consistent operation. The 4150 TapeStationDx targets lower-throughput labs, handling 1 to 16 samples in tube strips, while the 4200 TapeStationDx scales from 1 to 96 samples using tube strips or 96-well plates at a constant cost per sample. Both systems provide quality control results in about 1 to 2 minutes per sample. TapeStationDx software manages data acquisition, analysis, reporting and export, and includes audit trails and electronic signatures to help support compliance with regulations such as 21 CFR Part 11 and EU Annex 11.
The portfolio is available in the United States, Canada and selected European countries. Agilent reports fiscal 2025 revenue of $6.95 billion and around 18,000 employees worldwide.
Agilent Technologies (A) declared a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 6, 2026, to shareholders of record as of the close of business on October 28, 2026. The company states that the timing and amount of future dividends will depend on determinations by Agilent’s board of directors. In fiscal year 2025, Agilent generated $6.95 billion in revenue and employed approximately 18,000 people worldwide.
Agilent Technologies (A) declared a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 28, 2026 to shareholders of record as of the close of business on October 6, 2026. Future dividend timing and amounts will depend on determinations by Agilent’s board of directors. The company reports revenue of $6.95 billion for fiscal year 2025 and approximately 18,000 employees worldwide.
Agilent Technologies (A) will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference at 10 a.m. BST on Sept. 23, 2026, in London.
CEO Padraig McDonnell and CFO Adam Elinoff are scheduled to speak. A live audio webcast and replay of the presentation will be available via Agilent’s Investor Relations website. The company reports revenue of $6.95 billion for fiscal year 2025 and has approximately 18,000 employees worldwide.